Intracranial meningiomas: clinical, intrascopic and pathomorphological causes of recurrence (literature review)

Introduction. Meningiomas are the second most common central nervous system (CNS) tumors in adults. most meningiomas are benign tumors. Anaplastic and atypical meningiomas account for 25% and have a high recurrence rate even after radical tumor resection and radiotherapy. The prognosis of patients with anaplastic meningiomas remains disappointing; most of them die within the first 2 to 5 years after surgery. Purpose: to discuss the challenges in diagnosis and treatment of recurrent meningiomas, to identify the causes of tumor progression, and to assess the clinical features and radiographic findings as well as specific pathomorphological and molecular genetic characteristics. material and methods. We searched for publications in the Pubmed, EMBASE, Cohrane Library and eLibrary databases published between January 2000 and January 2019 on the issue of recurrent intracranial meningiomas, in particular atypical and anaplastic meningiomas. Results. The review systematizes data on the prognostic factors for survival, relapse-free period, and disease progression. particular attention was paid to the radical resection of the tumor and the assessment of the grade of anaplasia. The current data on radiotherapy and drug therapy were presented.  the controversial issues of approaches to the assessment of morphological prognostic criteria were discussed. The current knowledge on the most common genetic mutations in meningiomas, the prospects for their study and use for targeted therapy were presented. Conclusion. The management of meningioma still presents some unresolved issues.  There are no optimal standards for diagnosis and treatment of patients with meningiomas that would take into account biological characteristics, including growth characteristics and molecular genetic profile. There are no clear prognostic criteria for recurrence and continuity in further management after surgical treatment, which affects the mortality rate and quality of life in this category of patients. New fundamental data that will determine a different strategy in the treatment of intracranial meningiomas are needed.

1. Cushing H. The meningiomas (dural endotheliomas): their source and favored seats of origin (Cavendish Lecture). Brain. 1922 Oct; 45(2): 282–316. doi: 10.1093/brain/45.2.282.

2. Louis D.N., Perry A., Reifenberger G., von Deimling A., Figarella-Branger D., Cavenee W.K., Ohgaki H., Wiestler O.D., Kleihues P., Ellison D.W. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6): 803–20. doi: 10.1007/s00401-016-1545-1.

3. Ostrom Q.T., Patil N., Cioffi G., Waite K., Kruchko C., Barnholtz-Sloan J.S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. Neuro Oncol. 2020; 22. doi: 10.1093/neuonc/noaa200.

4. Ulitin A.Ju., Oljushin V.E., Poljakov I.V. Epidemiology of primary brain tumors in St. Petersburg. Zhurnal «Voprosy nejrohirurgii» imeni N.N. Burdenko. 2005; 1: 6–12. (in Russian).

5. Leães C.G., Meurer R.T., Coutinho L.B., Ferreira N.P., Pereira-Lima J.F., da Costa Oliveira M. Immunohistochemical expression of aromatase and estrogen, androgen and progesterone receptors in normal and neoplastic human meningeal cells. Neuropathology. 2010; 30(1): 44–9. doi: 10.1111/j.1440-1789.2009.01047.x.

6. Carroll R.S., Zhang J., Dashner K., Black P.M. Progesterone and glucocorticoid receptor activation in meningiomas. Neurosurgery. 1995; 37(1): 92–7. doi: 10.1227/00006123-199507000-00014.

7. Reubi J.C., Maurer R., Klijn J.G., Stefanko S.Z., Foekens J.A., Blaauw G., Blankenstein M.A., Lamberts S.W. High incidence of somatostatin receptors in human meningiomas: biochemical characterization. J Clin Endocrinol Metab. 1986; 63(2): 433–8. doi: 10.1210/jcem-63-2-433.

8. Louis D.N., Perry A., Wesseling P., Brat D.J., Cree I.A., Figarella-Branger D., Hawkins C., Ng H.K., Pfister S.M., Reifenberger G., Soffietti R., von Deimling A., Ellison D.W. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8): 1231–51. doi: 10.1093/neuonc/noab106.

9. Kitaev S.M., Kitaev S.V. Radiation diagnostics of brain diseases. MEDpress-inform. 2018. 136 p. (in Russian).

10. Osborn A., Zal’tsman K., Zaveri M. Radiation diagnostics. Brain. Izdatel’stvo Panfilova. 2018. 1216 p. (in Russian).

11. Kleinschmidt-DeMasters B.K., Rodriguez F., Tihan T. Diagnostic pathology: Neuropathology (2nd edition). Elsevier. 2016. 864 p.

12. Krotenkova M. B., Bryukhov V.V., Morozova S.N. Modern technologies of neuroimaging (lecture). Radiology-Practice. 2017; 2(62): 47–63. (in Russian).

13. Krivoshapkin A.L., Sergeev G.S., Kurbatov V.P., Gaitan A.S., Duishobaev A.R., Pyatov S.M., Mishinov S.V., Kal’neus L.E., Yanchenko A.A., Volkov A.M. Preoperative verification of histological type of meningeal tumors using magnetic resonance imaging data. Russian Journal of Neurosurgery. 2017; (3): 11–9. (in Russian).

14. Byvaltsev V.A., Stepanov I.A., Kichigin A.I., Antipina S.L. Diffusion-weighted MRI in the differential diagnosis of brain meningiomas. Siberian Journal of Oncology. 2017; 16(3): 19–26. (in Russian). doi: 10.21294/1814-4861-2017-16-3-19-26.

15. Khosten N., Libig T. Computed tomography of the head and spine. MEDpress-inform. 2017. 576 p. (in Russian).

16. Yakovlenko Yu.G., Moldovanov V.A., Araslanova L.V., Blinov I.M., Suhanova O.P. Preoperative evaluation of the venous system during the surgery of parasagittal meningioma. Medical Herald of the South of Russia. 2019; 10(1): 79–83. (in Russian). doi: 10.21886/2219-8075-2019-10-1-79-83.

17. Sergienko V.B., Ansheles A.A. Radionuclide diagnostics with neurotropic radiopharmaceuticals. Infra-M. 2016. 128 p. (in Russian).

18. Brodskaya Z., Skvortsova T., Malakhova E., Gurchin A., Panfilenko A., Medvedev S. PET diagnostics of intracranial meningiomas. Medical Visualization. 2012; 2: 18–29. (in Russian).

19. Shmyrev V., Vasil'ev A., Rudas M., Jazvenko A., Overchenko K. Positron emission tomography in neurological practice. Kremlevskaya meditsina. Klinicheskii vestnik. 2017; 1(4): 77–81. (in Russian).

20. Yao A., Sarkiss C.A., Lee J., Zarzour H.K., Shrivastava R.K. Surgical limitations in convexity meningiomas en-plaque: Is radical resection necessary? J Clin Neurosci. 2016; 27: 28–33. doi: 10.1016/j.jocn.2015.06.033.

21. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957; 20(1): 22–39. doi: 10.1136/jnnp.20.1.22.

22. Violaris K., Katsarides V., Sakellariou P. The Recurrence Rate in Meningiomas: Analysis of Tumor Location, Histological Grading, and Extent of Resection. Open J Modern Neurosurg. 2012; 2: 6–10. doi: 10.4236/ojmn.2012.21002.

23. Kotecha R.S., Pascoe E.M., Rushing E.J., Rorke-Adams L.B., Zwerdling T., Gao X., Li X., Greene S., Amirjamshidi A., Kim S.K., Lima M.A., Hung P.C., Lakhdar F., Mehta N., Liu Y., Devi B.I., Sudhir B.J., Lund-Johansen M., Gjerris F., Cole C.H., Gottardo N.G. Meningiomas in children and adolescents: a meta-analysis of individual patient data. Lancet Oncol. 2011; 12(13): 1229–39. doi: 10.1016/S1470-2045(11)70275-3.

24. Goldbrunner R., Minniti G., Preusser M., Jenkinson M.D., Sallabanda K., Houdart E., von Deimling A., Stavrinou P., Lefranc F., Lund-Johansen M., Moyal E.C., Brandsma D., Henriksson R., Soffietti R., Weller M. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016; 17(9): 383–91. doi: 10.1016/S1470-2045(16)30321-7.

25. Rogers L., Barani I., Chamberlain M., Kaley T.J., McDermott M., Raizer J., Schiff D., Weber D.C., Wen P.Y., Vogelbaum M.A. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2015; 122(1): 4–23. doi: 10.3171/2014.7.JNS131644.

26. Buerki R.A., Horbinski C.M., Kruser T., Horowitz P.M., James C.D., Lukas R.V. An overview of meningiomas. Future Oncol. 2018; 14(21): 2161–77. doi: 10.2217/fon-2018-0006.

27. Oya S., Kawai K., Nakatomi H., Saito N. Significance of Simpson grading system in modern meningioma surgery: integration of the grade with MIB-1 labeling index as a key to predict the recurrence of WHO Grade I meningiomas. J Neurosurg. 2012; 117(1): 121–8. doi: 10.3171/2012.3.JNS111945.

28. Reuss D.E., Piro R.M., Jones D.T., Simon M., Ketter R., Kool M., Becker A., Sahm F., Pusch S., Meyer J., Hagenlocher C., Schweizer L., Capper D., Kickingereder P., Mucha J., Koelsche C., Jäger N., Santarius T., Tarpey P.S., Stephens P.J., Andrew Futreal P., Wellenreuther R., Kraus J., Lenartz D., Herold-Mende C., Hartmann C., Mawrin C., Giese N., Eils R., Collins V.P., König R., Wiestler O.D., Pfister S.M., von Deimling A. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol. 2013; 125(3): 351–8. doi: 10.1007/s00401-013-1093-x.

29. Strickland M.R., Gill C.M., Nayyar N., D’Andrea M.R., Thiede C., Juratli T.A., Schackert G., Borger D.R., Santagata S., Frosch M.P., Cahill D.P., Brastianos P.K., Barker F.G. Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas. J Neurosurg. 2017; 127(2): 438–44. doi: 10.3171/2016.8.JNS161076.

30. Yesilöz Ü., Kirches E., Hartmann C., Scholz J., Kropf S., Sahm F., Nakamura M., Mawrin C. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence. Neuro Oncol. 2017; 19(8): 1088–96. doi: 10.1093/neuonc/nox018.

31. Walcott B.P., Nahed B.V., Brastianos P.K., Loeffler J.S. Radiation Treatment for WHO Grade II and III Meningiomas. Front Oncol. 2013; 3: 227. doi: 10.3389/fonc.2013.00227.

32. Aghi M.K., Carter B.S., Cosgrove G.R., Ojemann R.G., Amin-Hanjani S., Martuza R.L., Curry W.T. Jr., Barker F.G. Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery. 2009; 64(1): 56–60; discussion 60. doi: 10.1227/01.NEU.0000330399.55586.63.

33. Komotar R.J., Iorgulescu J.B., Raper D.M., Holland E.C., Beal K., Bilsky M.H., Brennan C.W., Tabar V., Sherman J.H., Yamada Y., Gutin P.H. The role of radiotherapy following gross-total resection of atypical meningiomas. J Neurosurg. 2012; 117(4): 679–86. doi: 10.3171/2012.7.JNS112113.

34. Dziuk T.W., Woo S., Butler E.B., Thornby J., Grossman R., Dennis W.S., Lu H., Carpenter L.S., Chiu J.K. Malignant meningioma: an indication for initial aggressive surgery and adjuvant radiotherapy. J Neurooncol. 1998; 37(2): 177–88. doi: 10.1023/a:1005853720926.

35. Rogers L., Barani I., Chamberlain M., Kaley T.J., McDermott M., Raizer J., Schiff D., Weber D.C., Wen P.Y., Vogelbaum M.A. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2015; 122(1): 4–23. doi: 10.3171/2014.7.JNS131644.

36. Central Nervous System Cancers [Internet]. NCCN Guidelines; 2021. URL:http://nccn.org/ [cited 2021 Dec 27].

37. Schrell U.M., Rittig M.G., Anders M., Koch U.H., Marschalek R., Kiesewetter F., Fahlbusch R. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg. 1997; 86(5): 840–4. doi: 10.3171/jns.1997.86.5.0840.

38. Newton H.B., Slivka M.A., Stevens C. Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neurooncol. 2000; 49(2): 165–70. doi: 10.1023/a:1026770624783.

39. Mason W.P., Gentili F., Macdonald D.R., Hariharan S., Cruz C.R., Abrey L.E. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg. 2002; 97(2): 341–6. doi: 10.3171/jns.2002.97.2.0341.

40. Rosenthal M.A., Ashley D.L., Cher L. Treatment of high risk or recurrent meningiomas with hydroxyurea. J Clin Neurosci. 2002; 9(2): 156–8. doi: 10.1054/jocn.2001.1019.

41. Paus S., Klockgether T., Urbach H., Schlegel U. Meningioma of the optic nerve sheath: treatment with hydroxyurea. J Neurol Neurosurg Psychiatry. 2003 Sep; 74(9): 1348–50. doi: 10.1136/jnnp.74.9.1348-a.

42. Loven D., Hardoff R., Sever Z.B., Steinmetz A.P., Gornish M., Rappaport Z.H., Fenig E., Ram Z., Sulkes A. Non-resectable slow-growing meningiomas treated by hydroxyurea. J Neurooncol. 2004; 67(1–2): 221–6. doi: 10.1023/b:neon.0000021827.85754.8e.

43. Hahn B.M., Schrell U.M., Sauer R., Fahlbusch R., Ganslandt O., Grabenbauer G.G. Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. J Neurooncol. 2005; 74(2): 157–65. doi: 10.1007/s11060-004-2337-3.

44. Weston G.J., Martin A.J., Mufti G.J., Strong A.J., Gleeson M.J. Hydroxyurea treatment of meningiomas: a pilot study. Skull Base. 2006; 16(3): 157–60. doi: 10.1055/s-2006-949518.

45. Swinnen L.J., Rankin C., Rushing E.J., Laura H.F., Damek D.M., Barger G.R. Phase II study of hydroxyurea for unresectable meningioma (Southwest Oncology Group S9811). J Clin Oncol. 2009; 27(15): 2063. doi: 10.1200/jco.2009.27.15_suppl.2063.

46. Chamberlain M.C., Johnston S.K. Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series. J Neurooncol. 2011; 104(3): 765–71. doi: 10.1007/s11060-011-0541-5.

47. Chamberlain M.C. Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. J Neurooncol. 2012; 107(2): 315–21. doi: 10.1007/s11060-011-0741-z.

48. Chamberlain M.C., Tsao-Wei D.D., Groshen S. Temozolomide for treatment-resistant recurrent meningioma. Neurology. 2004; 62(7): 1210–2. doi: 10.1212/01.wnl.0000118300.82017.f4.

49. Chamberlain M.C., Tsao-Wei D.D., Groshen S. Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol. 2006; 78(3): 271–6. doi: 10.1007/s11060-005-9093-x.

50. Chamberlain M.C. Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg. 1996; 84(5): 733–6. doi: 10.3171/ jns.1996.84.5.0733.

51. Kaba S.E., DeMonte F., Bruner J.M., Kyritsis A.P., Jaeckle K.A., Levin V., Yung W.K. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery. 1997; 40(2): 271–5. doi: 10.1097/00006123-199702000-00007.

52. Muhr C., Gudjonsson O., Lilja A., Hartman M., Zhang Z.J., Långström B. Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography. Clin Cancer Res. 2001; 7(8): 2269–76.

53. Chamberlain M.C., Glantz M.J. Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer. 2008; 113(8): 2146–51. doi: 10.1002/cncr.23803.

54. Grunberg S.M., Weiss M.H., Spitz I.M., Ahmadi J., Sadun A., Russell C.A., Lucci L., Stevenson L.L. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg. 1991; 74(6): 861–6. doi: 10.3171/jns.1991.74.6.0861.

55. Steven M., Grunberg C.R., Townsend J. Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma. Proc Am Soc Clin Oncol. 2001.

56. Grunberg S.M., Weiss M.H., Russell C.A., Spitz I.M., Ahmadi J., Sadun A., Sitruk-Ware R. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest. 2006; 24(8): 727–33. doi: 10.1080/07357900601062339.

57. Grunberg S.M., Weiss M.H. Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma. J Neurooncol. 1990; 8(1): 61–5. doi: 10.1007/BF00182088.

58. Jääskeläinen J., Laasonen E., Kärkkäinen J., Haltia M., Troupp H. Hormone treatment of meningiomas: lack of response to medroxyprogesterone acetate (MPA). A pilot study of five cases. Acta Neurochir (Wien). 1986; 80(1–2): 35–41. doi: 10.1007/BF01809555.

59. Markwalder T.M., Seiler R.W., Zava D.T. Antiestrogenic therapy of meningiomas--a pilot study. Surg Neurol. 1985; 24(3): 245–9. doi: 10.1016/0090-3019(85)90030-8.

60. Goodwin J.W., Crowley J., Eyre H.J., Stafford B., Jaeckle K.A., Townsend J.J. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol. 1993; 15(1): 75–7. doi: 10.1007/BF01050266.

61. Rünzi M.W., Jaspers C., Windeck R., Benker G., Mehdorn H.M., Reinhardt V., Reinwein D. Successful treatment of meningioma with octreotide. Lancet. 1989; 1(8646): 1074. doi: 10.1016/s0140-6736-(89)92465-3.

62. García-Luna P.P., Relimpio F., Pumar A., Pereira J.L., Leal-Cerro A., Trujillo F., Cortés A., Astorga R. Clinical use of octreotide in unresectable meningiomas. A report of three cases. J Neurosurg Sci. 1993; 37(4): 237–41.

63. Jaffrain-Rea M.L., Minniti G., Santoro A., Bastianello S., Tamburrano G., Gulino A., Cantore G. Visual improvement during octreotide therapy in a case of episellar meningioma. Clin Neurol Neurosurg. 1998; 100(1): 40–3. doi: 10.1016/s0303-8467(97)00110-8.

64. Johnson D.R., Kimmel D.W., Burch P.A., Cascino T.L., Giannini C., Wu W., Buckner J.C. Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma. Neuro Oncol. 2011; 13(5): 530–5. doi: 10.1093/neuonc/nor044.

65. Chamberlain M.C., Glantz M.J., Fadul C.E. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology. 2007; 69(10): 969–73. doi: 10.1212/01.wnl.0000271382.62776.b7.

66. Norden A.D., Ligon K.L., Hammond S.N., Muzikansky A., Reardon D.A., Kaley T.J., Batchelor T.T., Plotkin S.R., Raizer J.J., Wong E.T., Drappatz J., Lesser G.J., Haidar S., Beroukhim R., Lee E.Q., Doherty L., Lafrankie D., Gaffey S.C., Gerard M., Smith K.H., McCluskey C., Phuphanich S., Wen P.Y. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015; 84(3): 280–6. doi: 10.1212/WNL.0000000000001153.

67. Wen P.Y., Yung W.K., Lamborn K.R., Norden A.D., Cloughesy T.F., Abrey L.E., Fine H.A., Chang S.M., Robins H.I., Fink K., Deangelis L.M., Mehta M., Di Tomaso E., Drappatz J., Kesari S., Ligon K.L., Aldape K., Jain R.K., Stiles C.D., Egorin M.J., Prados M.D. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol. 2009; 11(6): 853–60. doi: 10.1215/15228517-2009-010.

68. Raizer J.J., Abrey L.E., Lassman A.B., Chang S.M., Lamborn K.R., Kuhn J.G., Yung W.K., Gilbert M.R., Aldape K.D., Wen P.Y., Fine H.A., Mehta M., Deangelis L.M., Lieberman F., Cloughesy T.F., Robins H.I., Dancey J., Prados M.D.; North American Brain Tumor Consortium. A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol. 2010; 12(1): 87–94. doi: 10.1093/neuonc/nop017.

69. Norden A.D., Raizer J.J., Abrey L.E., Lamborn K.R., Lassman A.B., Chang S.M., Yung W.K., Gilbert M.R., Fine H.A., Mehta M., Deangelis L.M., Cloughesy T.F., Robins H.I., Aldape K., Dancey J., Prados M.D., Lieberman F., Wen P.Y. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010; 96(2): 211–7. doi: 10.1007/s11060-009-9948-7.

70. Kaley T.J., Wen P., Schiff D., Ligon K., Haidar S., Karimi S., Lassman A.B., Nolan C.P., DeAngelis L.M., Gavrilovic I., Norden A., Drappatz J., Lee E.Q., Purow B., Plotkin S.R., Batchelor T., Abrey L.E., Omuro A. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015; 17(1): 116–21. doi: 10.1093/neuonc/nou148.

71. Puchner M.J.A., Hans V.H., Harati A., Lohmann F., Glas M., Herrlinger U. Bevacizumab-induced regression of anaplastic meningioma. Ann Oncol. 2010; 21(12): 2445–6. doi: 10.1093/annonc/mdq634.

72. Goutagny S., Raymond E., Sterkers O., Colombani J.M., Kalamarides M. Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab. Ann Oncol. 2011; 22(4): 990–1. doi: 10.1093/annonc/mdr012.

73. Wilson T.J., Heth J.A. Regression of a meningioma during paclitaxel and bevacizumab therapy for breast cancer. J Clin Neurosci. 2012; 19(3): 468–9. doi: 10.1016/j.jocn.2011.07.024.

74. Lou E., Sumrall A.L., Turner S., Peters K.B., Desjardins A., Vredenburgh J.J., McLendon R.E., Herndon J.E., McSherry F., Norfleet J., Friedman H.S., Reardon D.A. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012; 109(1): 63–70. doi: 10.1007/s11060-012-0861-0.

75. Nayak L., Iwamoto F.M., Rudnick J.D., Norden A.D., Lee E.Q., Drappatz J., Omuro A., Kaley T.J. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol. 2012; 109(1): 187–93. doi: 10.1007/s11060-012-0886-4.

76. Macdonald D.R., Cascino T.L., Schold S.C. Jr., Cairncross J.G. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8(7): 1277–80. doi: 10.1200/JCO.1990.8.7.1277.

77. Wen P.Y., Macdonald D.R., Reardon D.A., Cloughesy T.F., Sorensen A.G., Galanis E., Degroot J., Wick W., Gilbert M.R., Lassman A.B., Tsien C., Mikkelsen T., Wong E.T., Chamberlain M.C., Stupp R., Lamborn K.R., Vogelbaum M.A., van den Bent M.J., Chang S.M. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010; 28(11): 1963–72. doi: 10.1200/JCO.2009.26.3541.

78. Quant E.C., Wen P.Y. Response assessment in neuro-oncology. Curr Oncol Rep. 2011; 13(1): 50–6. doi: 10.1007/s11912-010-0143-y.

79. Kaley T., Barani I., Chamberlain M., McDermott M., Panageas K., Raizer J., Rogers L., Schiff D., Vogelbaum M., Weber D., Wen P. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol. 2014; 16(6): 829–40. doi: 10.1093/neuonc/not330.

80. Kaprin A.D., Ivanov S.A., Klimenko A.A. Prostate cancer: new opportunities in the diagnosis of localized and locally advanced forms of the disease. Andrology and Genital Surgery. 2006; 7(2): 14–9. (in Russian).

81. Barresi V., Lionti S., Caliri S., Caffo M. Histopathological features to define atypical meningioma: What does really matter for prognosis? Brain Tumor Pathol. 2018; 35(3): 168–80. doi: 10.1007/s10014-018-0318-z.

82. Nakaguchi H., Fujimaki T., Matsuno A., Matsuura R., Asai A., Suzuki I., Sasaki T., Kirino T. Postoperative residual tumor growth of meningioma can be predicted by MIB-1 immunohistochemistry. Cancer. 1999; 85(10): 2249–54.

83. Bertero L., Dalla Dea G., Osella-Abate S., Botta C., Castellano I., Morra I., Pollo B., Calatozzolo C., Patriarca S., Mantovani C., Rudà R., Tardivo V., Zenga F., Garbossa D., Papotti M., Soffietti R., Ricardi U., Cassoni P. Prognostic Characterization of Higher-Grade Meningiomas: A Histopathological Score to Predict Progression and Outcome. J Neuropathol Exp Neurol. 2019; 78(3): 248–56. doi: 10.1093/jnen/nly127.

84. Shan B., Zhang J., Song Y., Xu J. Prognostic factors for patients with World Health Organization grade III meningiomas treated at a single center. Medicine (Baltimore). 2017; 96(26). doi: 10.1097/MD.0000000000007385.

85. Li B., Tao B., Bai H., Zhong J., Wu X., Shi J., Sun H., Li S. Papillary meningioma: an aggressive variant meningioma with clinical features and treatment: a retrospective study of 10 cases. Int J Neurosci. 2016; 126(10): 878–87. doi: 10.3109/00207454.2015.1077833.

86. Surov A., Hamerla G., Meyer H.J., Winter K., Schob S., Fiedler E. Whole lesion histogram analysis of meningiomas derived from ADC values. Correlation with several cellularity parameters, proliferation index KI67, nucleic content, and membrane permeability. Magn Reson Imaging. 2018; 51: 158–62. doi: 10.1016/j.mri.2018.05.009.

87. Surov A., Meyer H.J., Wienke A. Associations between apparent diffusion coefficient (ADC) and KI67 in different tumors: a meta-analysis. Part 1: ADCmean. Oncotarget. 2017; 8(43): 75434–44. doi: 10.18632/oncotarget.20406.

88. Bi W.L., Greenwald N.F., Abedalthagafi M., Wala J., Gibson W.J., Agarwalla P.K., Horowitz P., Schumacher S.E., Esaulova E., Mei Y., Chevalier A., Ducar M., Thorner A.R., van Hummelen P., Stemmer-Rachamimov A., Artyomov M., Al-Mefty O., Dunn G.P., Santagata S., Dunn I.F., Beroukhim R. Genomic landscape of high-grade meningiomas. NPJ Genom Med. 2017; 2: 15. doi: 10.1038/s41525-017-0014-7.

89. Clark V.E., Erson-Omay E.Z., Serin A., Yin J., Cotney J., Ozduman K., Avşar T., Li J., Murray P.B., Henegariu O., Yilmaz S., Günel J.M., Carrión-Grant G., Yilmaz B., Grady C., Tanrikulu B., Bakircioğlu M., Kaymakçalan H., Caglayan A.O., Sencar L., Ceyhun E., Atik A.F., Bayri Y., Bai H., Kolb L.E., Hebert R.M., Omay S.B., Mishra-Gorur K., Choi M., Overton J.D., Holland E.C., Mane S., State M.W., Bilgüvar K., Baehring J.M., Gutin P.H., Piepmeier J.M., Vortmeyer A., Brennan C.W., Pamir M.N., Kiliç T., Lifton R.P., Noonan J.P., Yasuno K., Günel M. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science. 2013; 339(6123): 1077–80. doi: 10.1126/science.1233009.

90. Peyre M., Gauchotte G., Giry M., Froehlich S., Pallud J., Graillon T., Bielle F., Cazals-Hatem D., Varlet P., Figarella-Branger D., Loiseau H., Kalamarides M. De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors. Neuro Oncol. 2018; 20(8): 1113–21. doi: 10.1093/neuonc/nox231.

91. Gao F., Shi L., Russin J., Zeng L., Chang X., He S., Chen T.C., Giannotta S.L., Weisenberger D.J., Zada G., Mack W.J., Wang K. DNA methylation in the malignant transformation of meningiomas. PLoS One. 2013; 8(1). doi: 10.1371/journal.pone.0054114.

92. Sahm F., Schrimpf D., Stichel D., Jones D.T.W., Hielscher T., Schefzyk S., Okonechnikov K., Koelsche C., Reuss D.E., Capper D., Sturm D., Wirsching H.G., Berghoff A.S., Baumgarten P., Kratz A., Huang K., Wefers A.K., Hovestadt V., Sill M., Ellis H.P., Kurian K.M., Okuducu A.F., Jungk C., Drueschler K., Schick M., Bewerunge-Hudler M., Mawrin C., Seiz-Rosenhagen M., Ketter R., Simon M., Westphal M., Lamszus K., Becker A., Koch A., Schittenhelm J., Rushing E.J., Collins V.P., Brehmer S., Chavez L., Platten M., Hänggi D., Unterberg A., Paulus W., Wick W., Pfister S.M., Mittelbronn M., Preusser M., Herold-Mende C., Weller M., von Deimling A. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol. 2017; 18(5): 682–94. doi: 10.1016/S1470-2045(17)30155-9.

93. Shaikh N., Dixit K., Raizer J. Recent advances in managing/understanding meningioma. F1000Res. 2018; 7. doi: 10.12688/f1000research.13674.1.

94. Brastianos P.K., Horowitz P.M., Santagata S., Jones R.T., McKenna A., Getz G., Ligon K.L., Palescandolo E., Van Hummelen P., Ducar M.D., Raza A., Sunkavalli A., Macconaill L.E., Stemmer-Rachamimov A.O., Louis D.N., Hahn W.C., Dunn I.F., Beroukhim R. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013; 45(3): 285–9. doi: 10.1038/ng.2526.

95. Abedalthagafi M., Bi W.L., Aizer A.A., Merrill P.H., Brewster R., Agarwalla P.K., Listewnik M.L., Dias-Santagata D., Thorner A.R., Van Hummelen P., Brastianos P.K., Reardon D.A., Wen P.Y., Al-Mefty O., Ramkissoon S.H., Folkerth R.D., Ligon K.L., Ligon A.H., Alexander B.M., Dunn I.F., Beroukhim R., Santagata S. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 2016; 18(5): 649–55. doi: 10.1093/neuonc/nov316.

96. Janku F. Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients. Cancer Treat Rev. 2017; 59: 93–101. doi: 10.1016/j.ctrv.2017.07.005.

97. Basset-Séguin N., Hauschild A., Kunstfeld R., Grob J., Dréno B., Mortier L., Ascierto P.A., Licitra L., Dutriaux C., Thomas L., Meyer N., Guillot B., Dummer R., Arenberger P., Fife K., Raimundo A., Dika E., Dimier N., Fittipaldo A., Xynos I., Hansson J. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017; 86: 334–48. doi: 10.1016/j.ejca.2017.08.022.

98. de Bono J.S., De Giorgi U., Rodrigues D.N., Massard C., Bracarda S., Font A., Arranz Arija J.A., Shih K.C., Radavoi G.D., Xu N., Chan W.Y., Ma H., Gendreau S., Riisnaes R., Patel P.H., Maslyar D.J., Jinga V. Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss. Clin Cancer Res. 2019; 25(3): 928–36. doi: 10.1158/1078-0432.CCR-18-0981.

99. Goutagny S., Nault J.C., Mallet M., Henin D., Rossi J.Z., Kalamarides M. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol. 2014; 24(2): 184–9. doi: 10.1111/bpa.12110.

100. Di Vinci A., Brigati C., Casciano I., Banelli B., Borzì L., Forlani A., Ravetti G.L., Allemanni G., Melloni I., Zona G., Spaziante R., Merlo D.F., Romani M. HOXA7, 9, and 10 are methylation targets associated with aggressive behavior in meningiomas. Transl Res. 2012; 160(5): 355–62. doi: 10.1016/j.trsl.2012.05.007.

101. Harmancı A.S., Youngblood M.W., Clark V.E., Coşkun S., Henegariu O., Duran D., Erson-Omay E.Z., Kaulen L.D., Lee T.I., Abraham B.J., Simon M., Krischek B., Timmer M., Goldbrunner R., Omay S.B., Baranoski J., Baran B., Carrión-Grant G., Bai H., Mishra-Gorur K., Schramm J., Moliterno J., Vortmeyer A.O., Bilgüvar K., Yasuno K., Young R.A., Günel M. Integrated genomic analyses of de novo pathways underlying atypical meningiomas. Nat Commun. 2017; 8: 14433. doi: 10.1038/ncomms14433.

102. Kishida Y., Natsume A., Kondo Y., Takeuchi I., An B., Okamoto Y., Shinjo K., Saito K., Ando H., Ohka F., Sekido Y., Wakabayashi T. Epigenetic subclassification of meningiomas based on genome-wide DNA methylation analyses. Carcinogenesis. 2012; 33(2): 436–41. doi: 10.1093/carcin/bgr260.

103. Vengoechea J., Sloan A.E., Chen Y., Guan X., Ostrom Q.T., Kerstetter A., Capella D., Cohen M.L., Wolinsky Y., Devine K., Selman W., Barnett G.H., Warnick R.E., McPherson C., Chiocca E.A., Elder J.B., Barnholtz-Sloan J.S. Methylation markers of malignant potential in meningiomas. J Neurosurg. 2013; 119(4): 899–906. doi: 10.3171/2013.7.JNS13311.

104. Olar A., Wani K.M., Wilson C.D., Zadeh G., DeMonte F., Jones D.T., Pfister S.M., Sulman E.P., Aldape K.D. Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma. Acta Neuropathol. 2017; 133(3): 431–44. doi: 10.1007/s00401-017-1678-x.